Robinson, Simon
May 2006
ICIS Chemical Business;5/29/2006, Vol. 1 Issue 21, p10
Trade Publication
The article presents updates on the chemical industry in Europe. A dispute between energy group RAG and the German government threatens the timetable for an initial public offering of RAG in the fourth quarter of 2007 and creates uncertainty for Degussa. The European Union competition authority approved Bayer's planned friendly takeover of Schering, and did not impose any conditions on the move. A forecast claims that Dutch chemicals turnover will increase by 6% in 2006, driven by rises in output volume and higher prices.


Related Articles

  • Europe Watch. Robinson, Simon // ICIS Chemical Business;7/17/2006, Vol. 1 Issue 28, p10 

    The article presents an update on issues related to the chemical industry. Bayer was able to own 92.4 percent of Schering after July 6, 2006 closure. German energy group RAG plans to decrease few administrative jobs when it merges the holdings of chemical producer Degussa, power plant operator...

  • Too little, too late? Abbot, Alison // Nature;3/30/2006, Vol. 440 Issue 7084, p603 

    The article examines the merger activity in the pharmaceutical industry in Germany. It details Bayer AG's offer to buy Schering AG. According to pharmaceutical analysts, the merger will affect mid-sized drug companies. There are three ways for these companies to respond according to a report...

  • Bayer Makes Schering Offer Official; Schering Recommends Bid.  // Chemical Week;4/26/2006, Vol. 168 Issue 14, p5 

    The article reports on the official bid price for the acquisition of Schering released by Bayer in April 2006. According to Bayer, there is approximately €3 billion in liquidity available to finance the acquisition. The acquisition would increase the sales of Bayer that were generated by...

  • Consolidations, spinoffs shape business climate.  // Fairfield County Business Journal;02/28/2000, Vol. 39 Issue 9, p12 

    Focuses on the trends that will shape the business climate in Connecticut in 2000. Volatility due to Internet stocks; Shortage of capital for non-Internet initial public offerings; Mergers between banks, insurers and brokers; Competing takeovers by consolidating industries before deals are...

  • News in brief.  // Nature Reviews Drug Discovery;Jul2006, Vol. 5 Issue 7, p530 

    The article presents news briefs related to the recent developments in the pharmaceutical industry. Merck & Co. Inc.'s cervical cancer vaccine Gardasil has successfully passed the regulatory and scientific hurdles, but other hurdles might prove to be more problematic. Studies have shown that the...

  • Bayer Enters Exclusive Takeover Talks With Aventis CropScience.  // Chemical Market Reporter;7/16/2001, Vol. 260 Issue 3, p6 

    Reports that Bayer is in exclusive talks on the takeover of Aventis CropScience, the agrochemicals and crop biotechnology operation owned by Aventis and Schering AG. Benefits of the acquisition to Bayer; Cost of the acquisition; Reason for the selection of Bayer among several bidders, by Aventis.

  • Bayer-Schering combo a better fit? Mirasol, Feliza // Chemical Market Reporter;4/3/2006, Vol. 269 Issue 13, p22 

    The article reports on Bayer AG's bid to take over Schering AG which is expected to result in a leading specialized global pharmaceutical entity. The acquisition could bolster Bayer's HealthCare division, particularly in the area of pharmaceutical specialty products. Bayer's bid trumped Merck...

  • Bayer's Schering buy good move. Williams, Dede // ICIS Chemical Business;12/4/2006, Vol. 1 Issue 46, p10 

    The article focuses on the statement by Bayer chairman Werner Wenning regarding the impact of the acquisition of German drug maker Schering by Bayer. The consolidation of Schering contributed strongly to the expansion of quarterly sales, and Wenning said the takeover will boost full-year...

  • Bayer raises forecast, says Schering boosting profit.  // Chemical Business;Jul2007, Vol. 21 Issue 7, p95 

    The article reports on a profit forecast raised by Bayer AG from 2008 to 2010 after finding ways to obtain more administrative and research cost savings from the acquisition of Schering AG. It says that Bayer has increased its estimation for its profit margin by more than 20 percent in 2007. It...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics